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The Warburg Effect is a cellular phenomenon in cancer cells discovered by Otto Warburg 
in 1924.  His findings showed that in normoxic conditions tumor cells primarily use 
glycolysis for energy production instead of mitochondrial oxidative phosphorylation like 
normal cells.  This breakthrough has been the basis for much research.  It has resulted in 
a successful and widely-used cancer detection method, the positron emission tomography 
(PET) scan.  The PET scan uses radioactive isotopes and the fact that cancer cells exhibit 
higher rates of glycolysis to pinpoint tumors with advanced imaging tools.  Furthermore, 
Warburg’s work helped to show the potential for beneficial pharmaceuticals that could be 
developed by inhibiting certain chemical mechanisms of glycolysis to specifically target 
and kill cancer cells.  This review covers research that has used the Warburg effect as a 
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 In the first half of the 20th century, the cell biologist and Nobel laureate, Otto 
Warburg, discovered that cancer cells have much higher rates of glycolysis than normal, 
healthy cells, even in the presence of oxygen.  Warburg further postulated that cancerous 
growth is stimulated by cells mainly using the fermentation pathway to produce 
necessary energy [1].  Although a remarkable finding, Warburg’s research has not been a 
focus of much cancer research until recently [2].  Starting with the premise that cancerous 
cells display higher rates of glycolysis than healthy ones, researchers are looking into 
detection techniques and potential treatments that are selective for this increased rate.  
 
The Warburg Effect 
 
 In the 1920’s, Otto Warburg conducted a series of experiments where he 
compared the rate of oxygen consumption and the production of lactic acid, an end-
product of the fermentation pathway, between cancerous and healthy cells.  Warburg 
found that while both cultures of cells produce similar amounts of adenosine tri-
phosphate (ATP), oxygen consumption was higher in healthy cells and the amount of 
lactic acid produced was higher in cancerous cells [1] (See Figure 1.)  These findings led 
Warburg to his discovery that even under aerobic conditions cancerous cells selectively 
use the fermentation pathway to produce energy.  In a 1966 lecture by Warburg, he put 
forth that, “the prime cause of cancer is the replacement of the respiration of oxygen in 
normal body cells by a fermentation of sugar [3].”  In a summary of his findings a decade 
earlier in 1956, Warburg postulated that damage to the respiration pathway and the 
consequent reliance on fermentation even in aerobic conditions was a step in cellular 
carcinogenesis, not a symptom [1].   Formally stated, the Warburg effect is the metabolic 
2 
 
change observed in cancer cells from oxidative phosphorylation to glycolysis as the 
primary source of cellular energy.   
 There has been strong evidence suggesting that the Warburg effect is a necessary 
change in a cell before it has full-blown cancer, as Warburg himself posited.  For 
example, the hypoxic and thus anaerobic conditions found at solid tumor mass centers 
would require cells present there to rely on glycolysis.  Furthermore, the metabolic 
change also works to elicit multiple cellular response mechanisms that stem from the 
concentrations of intracellular compounds that are altered by the increased rate of 
glycolysis.  These cellular responses have been shown to cause distinct transformations 
like the upregulation of proteins such as hypoxia-inducible factor 1-α that help the tumor 
survive adverse conditions in which normal cells cannot persist [4-6] . 
 In a 2004 study, it was calculated that 62% of all known cancers show an 
increased expression of the genes involved in the glycolysis pathway [7].  The increase of 
glycolytic gene expression corroborates Warburg's finding.  Furthermore, this finding is 
very significant because it verifies researchers' efforts of studying glycolysis in such great 





Positron Emission Tomography 
 
Warburg believed that aerobic fermentation should not be used as a test condition 
for the detection of cancerous cells [1].  However, in direct contrast to his statement, 
positron emission tomography does just that.  The first positron emission tomography 
(PET) apparatus was created in 1953 and first used clinically in the 1960’s [8].  Since 
then, the technology has advanced to become a common cancer discovery device that 
tracks the 3D origin of emitted positrons and can be used to pinpoint anatomical locations 
with high rates of glycolysis [9] (See Figure 2). 
A PET scan begins with the intravenous injection of a radioactive tracer 
compound. In the detection of cancer, a substitute for glucose is used which is 
molecularly similar enough to be absorbed by cells.  The molecule used is 
fluorodeoxyglucose (FDG) where the fluorine molecule is the radioactive isotope 18F (2-
18F-fluoro-2-deoxy-D-glucose).  18F undergoes positive beta decay where the Coulomb 
repulsion forces in the nucleus provide the energy to convert a proton into a neutron, a 
neutrino and a positron [9].  The emitted positron will collide and annihilate with a 
nearby electron releasing two gamma rays at an approximately 180 degree angle [8].  The 
PET scanning machinery detects these two gamma rays and using computational 
software calculates the three-dimensional origin inside the body [9].  
 The Warburg effect comes into the PET scanning process because of the tracer 
molecule that is used.  Cancerous cells, due to their increased rate of glycolysis, as shown 
by the Warburg effect, take in greater amounts of glucose than healthy cells.  This 
difference in uptake is exploited by FDG since it is a molecular analog to glucose.  
Tumor cells thus accumulate a larger amount of FDG and as the radioactive fluorine 
4 
 
decays, the positron annihilation events can be localized to the precise loci of cancer cells 




The Warburg effect and the distinct differences it states exist between cancerous 
and healthy cells directly led researchers to look more deeply into the metabolic pathway.  
These investigations studied multiple proteins involved in cellular fermentation and 
respiration, as well as regulators of those processes and other glycolytic metabolites and 
enzymes.   
 
Hypoxia-Inducible Factor-1α  
 
One protein connected to the Warburg effect is hypoxia-inducible factor 1 (HIF-
1) and specifically the oxygen-regulated α subunit (HIF-1α) [4].  HIF-1α is normally 
expressed in cells under hypoxic conditions [5] and it serves to upregulate the production 
of proteins that help the cell survive and adapt to a reduced supply of oxygen [6] (See 
Figure 3).   It is important to note that in hypoxic conditions the rate of transcription of 
HIF-1α is substantially lower than the rate found in tumor cells in normoxic conditions.  
HIF-1α is post-transcriptionally activated in hypoxic cells to initiate the cell's response to 
the lack of oxygen  [10].  Some of the cellular adaptations that HIF-1α stimulates include 
the upregulation of red blood cell production [11, 12], increased transcription of vascular 
endothelial growth factor (VEGF) [12-14], and increased production and membranal 
localization of a glucose transporter, GLUT1 [14, 15].  While it still gives tumor cells a 
competitive advantage in normoxic conditions, the upregulation of HIF-1α in solid tumor 
masses provides an even bigger edge.  Many tumor microenvironments become so tightly 
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packed that oxygen is scarce and HIF-1α’s hyperactivity helps keep tumor cells alive 
[14]. 
Tumor cells in normoxic conditions show an overexpression of HIF-1α when 
compared to normal cells in the same environment [4].  The greater rate of aerobic 
glycolysis and lower rate of oxidative respiration in tumor cells leads to increased 
intracellular levels of glycolytic metabolites, specifically pyruvate [1].  Pyruvate 
promotes the production and stability of HIF-1α thus creating a positive feedback loop 




Another potential marker for cancer based upon the findings of Warburg is 
pyruvate kinase (PK).  In glycolysis, PK catalyzes the reaction of phosphoenolpyruvate 
into pyruvate by removing a phosphate group which PK uses to generate ATP.  A 
specific form of PK, embryonic M2, has been found exclusively in cancer cells without 
the presence of the normal M1 isoform [17].  Christofk et al. showed that suppressing 
PKM2 while artificially adding PKM1 effectively reversed the Warburg effect and 
promoted aerobic respiration [18].  Tumorigenesis is greatly reduced or inhibited all 
together in cells with PKM2 knockdown [18].  PKM2 has also been shown to be a 
response marker to hypoxia as it becomes actively transcribed under low-oxygen 
conditions [10].  HIF-1α is a known transcriptional activator of PKM2 [10, 19].  The 
regulatory relationship between PKM2 and HIF-1α makes them both good candidates for 






 In normal human cells, transketolase (TKT) is part of the metabolic pentose 
phosphate pathway.  The pentose phosphate pathway contains both an oxidative and a 
nonoxidative part making it similar to glycolysis and oxidative phosphorylation and thus 
another candidate for cancer research.  Certain carcinomas, specifically epithelial 
varieties, were shown to express a high level of transketolase-like-1 (TKTL1) [20].  
Furthermore, the cellular concentration of TKTL1 directly correlated to the patient 
prognosis and survival [20].  TKTL1 has also been linked to cancer proliferation and the 
general regulation of other TKT enzymes [21].  Specifically in ovarian cancer, TKTL1 
has been shown to be present at a higher rate and has also been linked to a poorer patient 
prognosis [22].   
 The importance of TKTL1 has not yet been fully elucidated, but progress has 
been made.  An experiment that constructed a plasmid containing a coding region for 
siRNA against TKTL1 showed a substantial decrease in cancerous proliferation when the 





Multiple avenues of treatment for cancer are being examined based upon 
Warburg’s findings.  These include inhibiting targets like upstream regulators and 
promoting the inhibitors of glycolysis.  Other methods selectively target and kill cells 




The compound 3-bromopyruvate (3-BrPA) was studied for its effects on 
glycolysis [23].  It functions by inhibiting the activity of hexokinase II, the enzyme that 
first phosphorylates glucose when it enters a cell to prevent glucose from freely diffusing 
out of the cell due to the natural diffusion potential created by the active cellular import 
of glucose [24].  Initial results with 3-BrPA show a significantly lower number of viable 
tumor cells than healthy cells when treated with 3-BrPA, as well as an appreciably 
decreased concentration of ATP in tumor cells versus healthy ones [23].  The decrease in 
ATP concentration leads to cell death by the activation via dephosphorylation of a 
proapoptotic protein BAD, a member of the Bcl-2 family [25].  The increase in cellular 
concentration of BAD occurs along with the movement of BAX from the cytosol into 
mitochondria, an increase of cytochrome c and other known precursors of apoptosis [23].  
Cell death occurs via this pathway at a much faster rate in tumor cells than in healthy 
cells due to the greater dependence of tumor cells on glycolysis than healthy ones for 
generation of ATP [23].   
3-BrPA is also a natural toxin to normal cells which presents a natural problem 
for its use as a pharmaceutical, but the understanding of its inhibition of hexokinase II 
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could lead to chemical derivatives that are less toxic but equally or more effective at 
targeting tumors.  The mechanism of toxicity may be due to 3-BrPA’s ability to alkylate a 
variety of compounds that could also produce a cytotoxic effect in cells outside of 
hexokinase II inhibition [26].   Given by localized injection in vivo, 3-BrPA has a higher 




Koningic acid (KA) blocks the enzymatic activity of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) by covalently altering a cysteine residue that is essential for 
GAPDH's metabolic function [28, 29].  GAPDH serves as a catalyst with inorganic 
phosphate and NAD for the conversion of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate, a crucial step in glycolysis.  The inhibition of GAPDH by KA 
causes cells that are dependent upon glycolysis to undergo apoptosis [30].  GAPDH’s 
function in glycolysis causes an increase of phosphofructosekinase (PFK) activity in the 
presence of KA [30].  PFK converts fructose-6-phosphate to fructose-1,6-bisphosphate, a 
precursor to GAPDH’s substrate, while consuming one molecule of ATP.  The increased 
activity of PFK in high-glycolytic cells only serves to further deplete ATP stores and, in 
the presence of glucose, prompts ATP-depletion related apoptosis by caspase 3 [30].  KA 
is only effective in cells with a supply of glucose otherwise alternate starvation-induced 
metabolic pathways may be initiated to prolong cell life and reestablish the tumor’s 
dominance [30].  
KA is not a viable option for human cancer therapy because of toxic effects on 
certain human cells that rely heavily upon glycolysis for energy, such as erythrocytes 




Inhibition of Hypoxia-Inducible Factor-1α 
  
 Due to the overexpression of HIF-1α in cancer cells [4], it is a natural target for 
therapeutic agents (See Figure 3).  One potential therapeutic agent is nitric oxide (NO).  
NO acts as an inhibitor of HIF-1α by enhancing the activity of HIF-1α-prolyl 
hydroxylase (HIF-PH) [31].  HIF-PH selectively ubiquitinates HIF-1α for degradation by 
a proteasome.  This ability of NO does require at least 1% oxygen concentration [31] so it 
may not be an ideal treatment for solid tumor masses, but could be used in addition to 
another drug. 
 FK228 is another candidate for HIF-1α suppression.  FK228 is a histone 
deacetylase (HDAC) inhibitor that has shown promise for decreasing cellular HIF-1α 
levels as well as lowering HIF-1α’s binding activity with DNA [32].  HDACs condense 
chromatin by removing acetyl groups that prevent DNA from binding with histones.  
FK228 specifically tightens the DNA that is used in the transcription of HIF-1 as well as 
the DNA regions to which HIF-1α acts as a transcription factor [32].   
 FK228 is currently undergoing clinical trials for use as a cancer therapeutic agent. 
 Direct downregulation of HIF-1α may also prove as a potential treatment.  Short 
interfering RNA, or RNAi, has been used to knockdown HIF-1α and has shown an effect 




An analog of glucose, 2-Deoxyglucose (2-DG), is known to compete with glucose 
for hexokinase II, an enzyme in glycolysis.  Hexokinase II phosphorylates 2-DG to 2-
DG-P but cannot progress further down the glycolytic pathway thus inhibiting 
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hexokinase II from phosphorylating glucose-6-phosphate.  Since 2-DG acts as an 
inhibitor to glycolysis it has the potential to select for cells using anaerobic respiration.  
The buildup of 2-DG in cells relying upon glycolysis for energy eventually becomes 
cytotoxic. Cells that are able to use oxidative phosphorylation can rely on other sources 
such as fats and proteins to produce ATP.  This was tested using osteosarcoma cells and 
healthy bone tissue.  Results showed that healthy cells had a 1300-fold increased 
resistance to the susceptibility of 2-DG’s cytotoxic effects versus the osteosarcoma cells 
[34].   
 As a cancer treatment, 2-deoxyglucose is promising, but its use is limited because 
of the cellular reaction that it induces.  2-DG makes ATP production via glycolysis 
increasingly difficult and thus limits the quantity of ATP present.  This activates 
increased production of HIF that increases transcription of hexokinase and the glucose 
transport protein, GLUT1 as well as translocation of GLUT1 to the cellular membrane.  
These two actions by HIF serve to make the cell less susceptible to 2-DG since glucose 
has more opportunities to enter the cell via GLUT1 and be phosphorylated by hexokinase 
[34].  Cancerous cells may be more susceptible to treatment with 2-DG in the presence of 
HIF inhibitors.   
2-DG has been shown to be a candidate for dual-drug treatment [35].  By 
understanding the glycolysis pathway and the precise effect 2-DG has on the metabolic 
process, it was studied in conjunction with 3-BrPA, a hexokinase inhibitor.  2-DG 
competes against glucose for phosphorylation by hexokinase II, 3-BrPA reduces the total 
number of active hexokinase II molecules in the cytosol.  Since both drugs work to 
inhibit glycolysis at the same point in the pathway they were good candidates to study for 
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a cooperative result.  Testing against rabbit tumor cells has shown that the synergistic 
effect of both drugs results in a strong inhibition of glycolysis and even cell death [24].    
However, this strong focus on one target in glycolysis pathway may prove harmful for 
certain healthy cells too.  Healthy cells will be less susceptible to treatment by 2-DG with 
3-BrPA because they can rely on other energy sources, like lipids and proteins, and 
oxidative phosphorylation, but human cells that use glucose as a primary energy source 
may be adversely affected. 
 
  
Inhibition of AMP-Activated Protein Kinase 
 
AMP-activated protein kinase (AMPK) is a cellular energy monitor that is 
activated by high levels of adenosine monophosphate (AMP), which can be induced by 
hypoxia.  While the extent of AMPK’s role in carcinogenesis is not fully elucidated, links 
have been made between AMPK activity and tumor survivability [36].  In addition, 
inhibition of AMPK has been shown to work synergistically with a chemotherapy agent, 
cisplatin, by readily inducing p53 mediated apoptosis [37].  This effect is believed to 
occur because cisplatin-induced cellular stress promotes the activity of AMPK which 
serves to protect the tumor by increasing ATP concentration and halting replication [37].   
 
Glucose Transport Proteins 
 
 Increased transcription of the membranal glucose transport protein GLUT1 has 
been linked to the presence of a malignancy [38].  This discovery ties into the effect HIF 
has on GLUT1 transcription [15], GLUT1’s role in cellular reproduction, and the results 
of PET scans because of the increased localization inside cancer cells of the glucose 
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analog FDG [9].  GLUT1 is a strong candidate for treatment because of cancer cells' 
dependency on it.   
GLUT1 inhibition has been studied in combination with an existing chemotherapy 
drug, daunorubicin.  Phloretin is a known inhibitor of glucose uptake [39].  Using 
phloretin to prevent glucose uptake and hinder glycolysis made tumor cells more 
vulnerable to daunorubicin and led to apoptosis [40].  
 The potential for GLUT1 as a target was further confirmed by transfecting cancer 
cells with antisense GLUT1 cDNA that successfully suppressed tumor growth.  In 
addition, monoclonal antibody treatment specific for GLUT1 has been shown to be 
efficacious in slowing tumor proliferation [41].  This treatment has also worked to 
improve the ability of other chemotherapy agents [41].  While antibody therapy looks 
promising results have only been gathered in vitro.  In vivo studies may show lethal 
effects on cell lines that exhibit high levels of GLUT1 such as erythrocytes and blood-
brain barrier epithelial cells. 
   
Oxythiamine 
 
Because of its high levels of expression in certain cancer lines, transketolase is a 
possible target for anticancer therapies.  Oxythiamine has shown potential as an 
inhibitory agent of TKT, a metabolic enzyme in the pentose phosphate pathway.  In vivo 
studies in mice resulted in a decrease in tumor growth without toxic effects [42].  While 
transketolase-like 1 (TKTL-1) siRNA has shown to be effective in restricting cancer 
proliferation [21],  oxythiamine has not been linked to decreased TKTL-1 expression 
[43].  As well as inhibiting TKT activity, oxythiamine is known to block pyruvate 
dehydrogenase [44] which could potentially lead to blocking aerobic respiration in 
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normal cells.   Oxythiamine has also been shown to work well in conjunction with 




 Lonidamine was an early candidate for cancer therapy because it was shown to 
inhibit glycolysis in tumor cells [45].  It is believed to act on mitochondrially-bound 
hexokinase but the exact mechanism is unknown.  Furthermore, lonidamine improves the 
success of the chemotherapy drug cisplatin [46].  Research with lonidamine and other 







Resveratrol is a polyphenol and phytoalexin that has been shown to promote 
tumor apoptosis [47, 48].  It works by both interfering with phosphatidylinositol-3-kinase 
(PI3K) signaling pathways as well as inhibiting glucose metabolism [48].  PI3Ks have a 
wide range of effects including the regulation of metabolism and cellular replication.  
Specifically, resveratrol decreased the activation of PI3K by reducing the 
phosphorylation of Akt, a PI3K upstream regulator [48].  In addition, Resveratrol was 
shown to decrease glycolysis through additional inhibitory effects on the PI3K pathway 
[48].  It has also been found to inhibit glucose intake in ovarian cancer cells [47]. 
Resveratrol is a naturally occurring compound in red grapes among other foods 








Table 1.  Summary of prospective therapeutic targets and the effect of selected drugs.   
 
Target Drug(s) Effect 
Hexokinase II 
2-DG Glycolysis inhibition leading to cell death 
3-BrPA Decrease in intracellular ATP; apoptosis 
Lonidamine Glycolysis inhibition 
GAPDH KA Apoptosis by caspase 3 
HIF-1α FK228 Histone condensation; HIF-1α downregulation NO HIF-1α ubiquitination and degradation 
GLUT1 mAb Reduced tumor proliferation 
Transketolase Oxythiamine TKT inhibition siRNA TKTL1 knockdown 







The Warburg effect, known for over 80 years, has provided the premise for 
numerous advances in cancer research.  There are still yet many areas that need to be 
elucidated. 
 
Pyruvate Kinase M2 
 
Even though PKM2 has been directly linked to the Warburg effect [18], the 
mechanism by which this occurs is unknown.  One possible explanation is that in tumor 
cells without PKM1, excess growth factor produced by other carcinogenetic processes 
may trigger the suppression of fructose-1,6-bisphosphate which is an allosteric activator 
of PKM2.  It has been suggested that without the activity of both PKM1 and PKM2 cells 
switch to aerobic glycolysis for energy production [18].   Another suggested explanation 
is that PKM1 and 2 play a role in intracellular metabolite motility and that PKM1 
upregulates the movement of pyruvate to the mitochondria, while PKM2 sequesters 
pyruvate to lactate dehydrogenase [18]. 
While certainly plausible, the precise pathway by which cellular metabolism 
switches from aerobic respiration to aerobic glycolysis and what function PKM2 has are 
not clear.  The interactions of PKM1 and 2 with pyruvate dehydrogenase and lactate 
dehydrogenase should be studied further to determine if there is preferential movement 






A plethora of research has been done connecting the upregulation of GLUT1 
transcription and increased localization of GLUT1 in the cellular membranes of tumor 
cells [15, 38].  The selective increased utilization of GLUT1 for glucose intake by cancer 
cells makes it a potent target for the development of therapeutic agents.  As was already 
mentioned, treatment by GLUT1 inhibition may adversely affect normal human cells that 
also rely heavily on GLUT1.  This problem could potentially be avoided by increasing 
the selectivity of the treatment or by using a lower dosage in combination with another 
drug.   
The monoclonal antibody inhibition of GLUT1 demonstrated by Rastogi et al. 
tested in vitro [41] should be repeated in an animal model to test for wider physiological 
toxicity.  Direct injection of the antibody treatment into a solid tumor mass may prove to 
limit any potential toxic effects.  Furthermore, studying different antibody doses in 
conjunction with chemotherapy agents in an animal model could increase the potency of 




While many of the aforementioned treatments only provide partially successful 
results, some may show further efficacy when used in combination with other treatments.  
Some studies have already been done that show the potential for synergistic effects.   
 
2-Deoxyglucose and Lonidamine 
 
Following in the footsteps of the study conducted utilizing both 3-BrPA and 2-DG 
[24], another study should be done looking at the effectiveness of 2-DG with lonidamine.  
2-DG and lonidamine both work to inhibit glycolysis at the conversion of glucose to 
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glucose-6-phosphate by hexokinase.  2-DG actively competes with the normal substrate 
of hexokinase II, glucose [34] and lonidamine has been shown to reduce the activity of 
hexokinase II altogether [45].  Using these two drugs together for treatment could prove 
to effectively decrease the rate of glycolysis in tumor cells more than either one 
individually and should be the subject of future research.   
Due to 2-DG’s strong inhibition of glycolysis it may prove to be harmful to 
certain human cell types that rely heavily on glucose for energy such as erythrocytes, 
epithelial cells in the brain, and male germ cells [26].  However, a clinical trial testing the 
efficacy and safety of 2-DG administration in coordination with radiation therapy showed 
that it could be given safely to patients at 250mg/kg [35].  
 
2-Deoxyglucose and HIF Inhibition 
 
The main efficacy problem with 2-DG as a cancer therapeutic is the intrinsic 
cellular response that follows its absorption and interaction with hexokinase.  The 
scarcity of ATP caused by 2-DG competition with glucose stimulates a cell stress 
response mediated by HIF that amplifies the transcription of hexokinase, increasing the 
quantity of the molecule that 2-DG and glucose compete over, and also promotes the 
transcription and translocation of GLUT1 to the membrane, thereby increasing the uptake 
of both 2-DG and glucose into the cell from the extracellular environment.  This natural 
cell response makes the effective dose of 2-DG very high and thus more likely toxic to 
healthy cells [34].   
To circumvent this cellular response, a combined treatment with NO or FK228 
may prove to be a viable option.  By downregulating the transcription of HIF-1α, the 
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cellular stress response to 2-DG and the induced ATP shortage may be restricted and thus 








 Although the Warburg effect has led to many promising advances in the study of 
cancer, alternate theories exist that present contradictory evidence.  One such theory 
involves cancer cells using glutamine metabolism in the citric acid (TCA) cycle [49] (See 
Figure 4).  This is particularly controversial because one of the main facets of Warburg's 
theory is that oxidative metabolism is damaged and glycolysis is the pathway used to 
meet the tumor's energy needs.  In tumor cells, glutamine metabolism has been 
specifically linked to the production of oxaloacetate, which is a required molecule for the 
first step in the TCA cycle.  In healthy cells undergoing rapid growth, the consumption of 
glutamine is exhibited at high rates.  In cancer cells, this base utilization has additionally 
been tied to an increase of NADPH production by malic enzyme that suggests that 
glutamine may also play a role in the synthesis of fatty acids and nucleotides, potentially 
from precursors in the TCA cycle, that may be critical to tumor proliferation [49].   
 With the TCA cycle active in cancer cells, this knowledge goes beyond Warburg's 
theory because it opens up many potential biosynthetic pathways that could contribute to 
the maintenance and growth of cancer cells.  Additionally, certain cancers have been 
shown to not exhibit the Warburg effect.  This may be because they do not use glucose as 
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their primary source of energy and instead rely on another molecule.  Glutamine is an 
interesting candidate for further research because it may provide another target for 







A report released by the American Cancer Society estimates 1,437,180 new 
cancer cases in the United States in 2008.  This report also states that approximately one 
out of every four deaths in the US is cancer related [51].  These statistics clearly show the 
importance and need for cancer research.  In the 84 years since Otto Warburg 
demonstrated aerobic glycolysis as a trait of tumor cells, scientific progress has been 
immense.  The PET scan has been proven to be an effective, safe and non-invasive 
detection tool.  Many drug candidates such as FK228, 2-DG and 3-BrPA have shown 
promising results [23, 32, 34]. 
Research on cancer is far from over.  Efforts must continue to improve drug 
therapy and to find the most efficacious and safe treatments.  Studies looking into other 
detection methods such as screening for genetic predispositions should still be carried on.  
To this end, research needs to be done to gain a better understanding of the exact cause 
for the hypoxic response and the unique metabolic profile exhibited by tumor cells that is 
already advantageously used by existing therapies.  This information will be an 




Figure 1.  Summary of cellular metabolism. (Source: Garber, K., Energy Boost: The 
Warburg Effect Returns in a New Theory of Cancer. J. Natl. Cancer Inst., 2004. 96(24): 




Figure 2.  (a) Schematic drawing of a PET machine.  (b) Concept drawing of positron 
decay. (Source: Brownell, G.L., et al., Positron Tomography and Nuclear Magnetic 




Figure 3. Hypoxia-Inducible Factor 1α Regulatory Pathway. (Source: Semenza, G.L., 
Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003. 3(10): p. 721-732.)  HIF-1α 
is a transcription factor that activates the synthesis of numerous proteins that promote 
angiogensis, cellular growth and metabolism, and survival pathways.  Study of the 





Figure 4.  The TCA cycle  
(Source:  http://en.wikipedia.org/wiki/File:Citric_acid_cycle_with_aconitate_2.svg.   
Licensed under the GNU Free Documentation License.  Accessed 19 January 2008.)   
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